Abstract
Activated Cancer Therapy (ACT), also known as Sonodynamic Photodynamic Therapy (SPDT) is a novel therapeutic modality that utilises a non-toxic photosensitive agent with reported ultrasound-activated properties. SPDT has previously demonstrated significant tumour cell inhibition in animal studies. There has been much research into the efficacy of photodynamic therapy and development in understanding of the underlying mechanism of tumour cytotoxicity. Synergistic ultrasound activation represents a promising development to activated sensitiser therapy, as photo-activation is limited by access and penetrance issues. Ultrasound has been demonstrated to activate a number of sono-sensitive agents allowing the possibility of non-invasive targeted treatment of deeper tumour sites than is currently achievable with photodynamic therapy. This case series of 115 patients with a variety of cancer diagnoses reports on experiences of this treatment over a 4 year period using sublingual administration of a new dual activation agent, Sonnelux-1, followed by a protocol of LED light and low-intensity ultrasound exposure. Initial clinical observation suggests SPDT is worthy of further investigation as an effective and well tolerated treatment for a wide variety of primary and metastatic tumours, including those refractory to chemotherapy.
Keywords: Sonodynamic therapy, photodynamic therapy, activated cancer therapy, ultrasound activated therapy, metastatic cancer, sonnelux-1, dove clinic, sonnemed
Current Drug Therapy
Title: Activated Cancer Therapy Using Light and Ultrasound - A Case Series of Sonodynamic Photodynamic Therapy in 115 Patients Over a 4 Year Period
Volume: 4 Issue: 3
Author(s): Julian Norman Kenyon, Richard James Fulle and Thomas Joseph Lewis
Affiliation:
Keywords: Sonodynamic therapy, photodynamic therapy, activated cancer therapy, ultrasound activated therapy, metastatic cancer, sonnelux-1, dove clinic, sonnemed
Abstract: Activated Cancer Therapy (ACT), also known as Sonodynamic Photodynamic Therapy (SPDT) is a novel therapeutic modality that utilises a non-toxic photosensitive agent with reported ultrasound-activated properties. SPDT has previously demonstrated significant tumour cell inhibition in animal studies. There has been much research into the efficacy of photodynamic therapy and development in understanding of the underlying mechanism of tumour cytotoxicity. Synergistic ultrasound activation represents a promising development to activated sensitiser therapy, as photo-activation is limited by access and penetrance issues. Ultrasound has been demonstrated to activate a number of sono-sensitive agents allowing the possibility of non-invasive targeted treatment of deeper tumour sites than is currently achievable with photodynamic therapy. This case series of 115 patients with a variety of cancer diagnoses reports on experiences of this treatment over a 4 year period using sublingual administration of a new dual activation agent, Sonnelux-1, followed by a protocol of LED light and low-intensity ultrasound exposure. Initial clinical observation suggests SPDT is worthy of further investigation as an effective and well tolerated treatment for a wide variety of primary and metastatic tumours, including those refractory to chemotherapy.
Export Options
About this article
Cite this article as:
Kenyon Norman Julian, Fulle James Richard and Lewis Joseph Thomas, Activated Cancer Therapy Using Light and Ultrasound - A Case Series of Sonodynamic Photodynamic Therapy in 115 Patients Over a 4 Year Period, Current Drug Therapy 2009; 4 (3) . https://dx.doi.org/10.2174/157488509789055036
DOI https://dx.doi.org/10.2174/157488509789055036 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
Call for Papers in Thematic Issues
Novel Therapeutic Approaches and Biomarkers for Chronic Kidney Disease (CKD)
The thematic issue on "Novel Therapeutic Approaches and Biomarkers for CKD" aims to provide a comprehensive exploration of cutting-edge strategies for the management of chronic kidney disease (CKD). This issue will delve into emerging therapeutic targets, focusing on critical aspects such as podocyte injury, endothelial dysfunction, and tubulointerstitial fibrosis, which ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Dysregulated Post-Transcriptional Control of COX-2 Gene Expression in Cancer
Current Pharmaceutical Design Cellular Based Cancer Vaccines: Type 1 Polarization of Dendritic Cells
Current Medicinal Chemistry Strategies that Target Tight Junctions for Enhanced Drug Delivery
Current Pharmaceutical Design Drug Delivery Systems and Strategies to Overcome the Barriers of Brain
Current Pharmaceutical Design A3 Receptor Ligands: Past, Present and Future Trends
Current Topics in Medicinal Chemistry Inhibition of Glycolysis and Glutaminolysis: An Emerging Drug Discovery Approach to Combat Cancer
Current Topics in Medicinal Chemistry Regulation of p53 Activity
Current Chemical Biology Genes Involved in Hereditary Hearing Impairment
Current Genomics Approaches to Gastrointestinal Cytoprotection: From Isolated Cells, Via Animal Experiments to Healthy Human Subjects and Patients with Different Gastrointestinal Disorders
Current Pharmaceutical Design Current Drug Targets for Modulating Alzheimer's Amyloid Precursor Protein: Role of Specific Micro-RNA Species
Current Medicinal Chemistry High Throughput Screening of Normal and Neoplastic Tissue Samples
Combinatorial Chemistry & High Throughput Screening Procyanidins and Their Healthy Protective Effects Against Type 2 Diabetes
Current Medicinal Chemistry A Rationale for the Use of Proton Pump Inhibitors as Antineoplastic Agents
Current Pharmaceutical Design Chalcone-thiosemicarbazone Hybrids as Inhibitors of Human Hepatocellular Carcinoma HepG2 Cells Viability and Oxygen Consumption
Current Bioactive Compounds Cancer Stem Cell Model in Oral Squamous Cell Carcinoma
Current Stem Cell Research & Therapy Prognostic Value and Clinicopathological Differences of Bmi1 in Gastric Cancer: A Meta-analysis
Anti-Cancer Agents in Medicinal Chemistry The Expanding Role of APRIL in Cancer and Immunity
Current Molecular Medicine Monoamine Receptors and Signal Transduction Mechanisms in Suicide
Current Psychiatry Reviews Electrochemotherapy as First Line Cancer Treatment: Experiences from Veterinary Medicine in Developing Novel Protocols
Current Cancer Drug Targets PACAP and Its Receptors Exert Pleiotropic Effects in The Nervous System by Activating Multiple Signaling Pathways
Current Protein & Peptide Science